Anti-Diabetesm & Anti-Cancer Biopharmaceuticals- Biogenomics

Biopharmaceuticals

Pipeline

Product

Indication

Discovery

Preclinicals

Clinical Trials

Approval

Launched

Insulin Aspart

(Biosimilar to: Novolog) ®

Rapid acting insulin analogue for treatment of type 1 & 2 diabetes mellitus

Insulin Aspart mix

(Biosimilar to: Novomix) ®

Combination of a rapid acting insulin and an intermediate acting type insulin for treatment of type 1 & 2 diabetes mellitus

Insulin Glargine

(Biosimilar to: Lantus) ®

Long-acting Insulin glargine for treatment of type 1 & 2 diabetes mellitus

Insulin Lispro

(Biosimilar to: Humalog) ®

Rapid acting insulin analogue for the treatment of type 1 & 2 diabetes mellitus

Insulin Degludec

(Biosimilar to: Tresiba) ®

Ultra long-acting insulin for the treatment of type 1 & 2 diabetes mellitus

Insulin Degludec + Aspart

(Biosimilar to: Ryzodeg) ®

Dual insulin combination to manage diabetes by keeping blood sugar in type 1 & 2 diabetes mellitus

Insulin Aspart pump

Insulin aspart pump delivers tiny amounts of insulin every few minutes

Liraglutide

(Biosimilar to: Victoza) ®

GLP -1 Reduce risk of cardiovascular events in Type 2 diabetes mellitus patients

Liraglutide + Insulin Aspart

GLP & rapid acting insulin for treating type 1 & 2, also reduce risk of cardiovascular events in type 2 diabetes mellitus and

BGN -25

Ointment for diabetic foot ulcers

Tirzepatide

(Reference to: Mounjaro) ®

Dual agonist for GLP and GIP peptide for treatment of type 2 diabetes mellitus

Exenatide

(Reference to: Byetta) ®

GLP-1 Analog for treatment of type 2 diabetes mellitus

Liraglutide + Degludec

(Reference to: Xultophy) ®

GLP-1 and long-acting insulin for the treatment of type 2 diabetes mellitus

Pembrolizumab

(Biosimilar to: Keytruda) ®

Anti PD-1 Pathway for cancer treatment

Nivelumab

(Biosimilar to: Opdiva) ®

To treat melanoma and other cancers

Pipeline

The pharmaceutical portfolio of BioGenomics focuses on anti-diabetes and anti-cancer segments since these two segments have a high impact on the quality of life.

The anti-diabetes range of products is the most comprehensive one at BioGenomics. Human Insulin, Insulin Aspart (Rapid and Mix), Insulin Glargine, Insulin Lispro have already completed development and are undergoing clinical trials. GLP-1 inhibitors and other advanced analogs are in development stages.

The anti-cancer pipeline of BioGenomics consists of Filgrastim and its PEGylated forms and various monoclonal antibodies. Filgrastim is currently in clinical trials and various monoclonal antibodies are in development stages.

There is an ongoing demand for these products due to emerging newer drug delivery systems and ever expanding indications.